Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Breast cancer, female
Stage/Subtype:  stage II breast cancer
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 89 for your search:
Start Over
Safety and Efficacy Study of the Xoft® Axxent® eBx™ IORT System
Phase: Phase IV
Type: Treatment
Age: 40 and over
Trial IDs: CTPR-0009, NCI-2013-01601, NCT01644669
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane with or without Chemotherapy in Treating Patients with Invasive RxPONDER Breast Cancer
Phase: Phase III
Type: Health services research, Treatment
Age: 18 and over
Trial IDs: S1007, NCI-2011-02623, CDR0000692475, PS1007_A11PAMDREVW01, SWOG-S1007, NCT01272037
Testosterone in Treating Postmenopausal Patients with Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 18 and over
Trial IDs: A221102, NCI-2012-00719, CDR0000730083, CALGB-A221102, NCCTG-N10C7, NCT01573442
Hormone Therapy with or without Everolimus in Treating Patients with Breast Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: S1207, NCI-2012-01995, CDR0000738280, SWOG-S1207, NCT01674140
Standard or Comprehensive Radiation Therapy in Treating Patients with Early-Stage Breast Cancer Previously Treated with Chemotherapy and Surgery
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NSABP-B-51/RTOG-1304, NCI-2012-03198, NSABP PROTOCOL B-51/RTOG PROTOCOL 1304, NSABP-B-51, NCT01872975
Lymph Node Dissection and Radiation Therapy in Treating Patients with Breast Cancer Previously Treated with Chemotherapy and Surgery
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: A011202, NCI-2013-00875, NCT01901094
Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients with Stage II-III Breast Cancer Undergoing Surgery
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: A011106, NCI-2013-01340, NCT01953588
Olaparib in Treating Patients with Triple-Negative Non-metastatic Breast Cancer Who Have Completed Definitive Local Treatment and Chemotherapy
Phase: Phase III
Type: Natural history/Epidemiology, Treatment
Age: 18 and over
Trial IDs: NSABP-B-55, NCI-2014-00644, BIG 6-13, D081CC00006, NCT02032823
Platinum Based Chemotherapy or Observation in Treating Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: EA1131, NCI-2014-01820, NCT02445391
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel with or without Carboplatin in Treating Patients with Triple-Negative Breast Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NRG-BR003, NCI-2015-00128, NRG-BR1428, NCT02488967
Triciribine Phosphate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients with Stage IIB-IV Breast Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: Over 18
Trial IDs: 2011-269, NCI-2013-01311, 007884, 11-051, TCN-PM, NCT01697293
Accelerated Intensity-Modulated Radiation Therapy in Treating Patients with Stage II-III Breast Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 36 to 90
Trial IDs: NYU 09-0623, NCI-2010-02263, 09-0623, NCT02308488
Docetaxel or Doxorubicin Hydrochloride and Cyclophosphamide Before Surgery in Treating Patients With Breast Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: H-16039, NCI-2012-00652, NCT00206518
Anastrozole With or Without Fulvestrant in Treating Postmenopausal Patients With Hormone Receptor Positive Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: H-20431, NCI-2012-00645, NCT00570323
Docetaxel and Cyclophosphamide in Treating Patients with Hormone-Receptor Positive Early Stage Breast Cancer Undergoing Surgery
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: WCI 1505-08, NCI-2011-03383, NCT00832338
Accelerated Whole Breast Radiotherapy in Treating Patients with Breast Cancer Who Have Undergone Surgery
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 040807, NCI-2012-00535, CDR0000643276, CINJ-040807, NCT00909909
Control or Extended Lapatinib Ditosylate and Trastuzumab With or Without Goserelin Acetate or Letrozole in Treating Patients With HER2-Positive Breast Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: TBCRC 023, NCI-2012-01766, H-25846, NCT00999804
I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 097517, NCI-2015-00014, NCT01042379
Laboratory Treated T Cells after Chemotherapy in Treating Patients with HER2-Negative Stage II-III Breast Cancer That Can Be Removed by Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2010-056, NCI-2011-02634, 1005008403, CDR0000675211, NCT01658969, WSU-2010-056, NCT01147016
Radiation Therapy in Treating Patients With Breast Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2009-0818, NCI-2011-01102, NCT01245712
Biological Therapy in Improving Immune Reconstitution after Chemotherapy in Older Patients with Stage I-III Breast, Stage II Bladder, or Stage II-III Colorectal Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 60 and over
Trial IDs: 11-C-0146, NCI-2013-01487, 110146, P09590, NCT01339000
Start Over